Literature DB >> 28331765

Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer.

Mesut Öztürk1, Ahmet Veysel Polat1, Yurdanur Süllü2, Leman Tomak3, Ayfer Kamalı Polat4.   

Abstract

OBJECTIVE: To assess the relationship between background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) proportion on breast magnetic resonance imaging (MRI) and hormone receptor expression and molecular subtypes in invasive breast cancer.
MATERIALS AND METHODS: This retrospective study enrolled 75 breast cancer patients who underwent breast MRI before treatment. T1-weighted images were reviewed to determine the FGT proportion, and contrast-enhanced fat-suppressed T1-weighted images were reviewed to determine BPE. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2-neu (HER2) status, and molecular subtypes of the tumors were compared with the BPE and FGT proportions.
RESULTS: Women with high BPE tended to have increased rate of ER and PR positive tumors (p=0.018 and p=0.013). FGT proportion was associated with ER positivity (p=0.009), but no significant differences between FGT proportion and PR positivity were found (p=0.256). There was no significant difference between HER2 status and any of the imaging features (p=0.453 and p=0.922). For premenopausal women, both FGT proportion and BPE were associated with molecular subtypes (p=0.025 and p=0.042). FGT proportion was also associated with BPE (p<0.001).
CONCLUSION: In women with invasive breast cancer, both high FGT containing breasts and high BPE breasts tended to have ER positive tumors.

Entities:  

Keywords:  Breast neoplasms; enhancement; hormone receptor; magnetic resonance imaging; molecular subtypes

Year:  2017        PMID: 28331765      PMCID: PMC5351461          DOI: 10.5152/tjbh.2016.3247

Source DB:  PubMed          Journal:  J Breast Health        ISSN: 1306-0945


  28 in total

Review 1.  Diagnostic breast MR imaging: current status and future directions.

Authors:  Elizabeth A Morris
Journal:  Radiol Clin North Am       Date:  2007-09       Impact factor: 2.303

2.  Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.

Authors:  Maciej A Mazurowski; Jing Zhang; Lars J Grimm; Sora C Yoon; James I Silber
Journal:  Radiology       Date:  2014-07-15       Impact factor: 11.105

3.  Normal breast parenchyma: contrast enhancement kinetics at dynamic MR mammography--influence of anthropometric measures and menopausal status.

Authors:  Katrin Hegenscheid; Carsten O Schmidt; Rebecca Seipel; René Laqua; Ralf Ohlinger; Jens-Peter Kühn; Norbert Hosten; Ralf Puls
Journal:  Radiology       Date:  2012-09-27       Impact factor: 11.105

4.  The association between biological subtype and isolated regional nodal failure after breast-conserving therapy.

Authors:  Jennifer Y Wo; Alphonse G Taghian; Paul L Nguyen; Rita Abi Raad; Meera Sreedhara; Jennifer R Bellon; Julia S Wong; Michele A Gadd; Barbara L Smith; Jay R Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

5.  Mammographic densities and risk of breast cancer.

Authors:  A F Saftlas; R N Hoover; L A Brinton; M Szklo; D R Olson; M Salane; J N Wolfe
Journal:  Cancer       Date:  1991-06-01       Impact factor: 6.860

6.  Mammographic density and hormone receptor expression in breast cancer: the Multiethnic Cohort Study.

Authors:  Shannon M Conroy; Ian Pagano; Laurence N Kolonel; Gertraud Maskarinec
Journal:  Cancer Epidemiol       Date:  2011-01-17       Impact factor: 2.984

7.  Subtypes of breast cancer show preferential site of relapse.

Authors:  Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Correlation between breast density in mammography and background enhancement in MR mammography.

Authors:  R Cubuk; N Tasali; B Narin; F Keskiner; L Celik; S Guney
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

9.  Breast cancer risk factors in relation to breast density (United States).

Authors:  Linda Titus-Ernstoff; Anna N A Tosteson; Claudia Kasales; Julia Weiss; Martha Goodrich; Elizabeth E Hatch; Patricia A Carney
Journal:  Cancer Causes Control       Date:  2006-12       Impact factor: 2.506

10.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

View more
  5 in total

1.  High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.

Authors:  Chuanhui Xu; Jinhui Yu; Feifei Wu; Xuemei Li; Dongmin Hu; Guiming Chen; Gang Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Fully automatic quantification of fibroglandular tissue and background parenchymal enhancement with accurate implementation for axial and sagittal breast MRI protocols.

Authors:  Dong Wei; Nariman Jahani; Eric Cohen; Susan Weinstein; Meng-Kang Hsieh; Lauren Pantalone; Despina Kontos
Journal:  Med Phys       Date:  2020-11-27       Impact factor: 4.071

3.  Preliminary study on discriminating HER2 2+ amplification status of breast cancers based on texture features semi-automatically derived from pre-, post-contrast, and subtraction images of DCE-MRI.

Authors:  Lirong Song; Hecheng Lu; Jiandong Yin
Journal:  PLoS One       Date:  2020-06-17       Impact factor: 3.240

4.  Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer.

Authors:  Jun Li; Yin Mo; Bo He; Qian Gao; Chunyan Luo; Chao Peng; Wei Zhao; Yun Ma; Ying Yang
Journal:  Br J Radiol       Date:  2019-08-09       Impact factor: 3.039

5.  Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.

Authors:  Alex Anh-Tu Nguyen; Vignesh A Arasu; Fredrik Strand; Wen Li; Natsuko Onishi; Jessica Gibbs; Ella F Jones; Bonnie N Joe; Laura J Esserman; David C Newitt; Nola M Hylton
Journal:  Tomography       Date:  2020-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.